OBJECTIVE: Clinically, vaginal progesterone (VP) and 17 alpha-hydroxyprogesterone
caproate (17P) have been shown to prevent preterm birth (PTB) in high-risk populations. We …

In the 1930s the “progestin” hormone produced by the corpus luteum was isolated and
found to be a Δ 4-keto-steroid. It was aptly named progesterone (P4) and in the following 30 …

Preterm delivery (PTD) is defined by the World Health Organization as birth before 37
completed weeks of gestation. In Western countries, PTD accounts for over 75% of all …

Progestogens for the prevention of preterm birth have a long history. In 2003, two widely
publicized double‐blind trials, one of daily vaginal progesterone suppositories and the other …

The safety of supplemental progestin therapy during pregnancy reflects whether an agent
exclusively promotes or potentially inhibits progestational cellular functions and whether …

Progestogens are the first drugs to demonstrate reproducibly a reduction in the rate of early
preterm birth. The efficacy and safety of progestogens are related to individual …

OBJECTIVE: We sought to provide evidence-based guidelines for using progestogens for
the prevention of preterm birth (PTB). METHODS: Relevant documents, in particular …

OBJECTIVE: We sought to provide evidence-based guidelines for using progestogens for
the prevention of preterm birth (PTB). METHODS: Relevant documents, in particular …

The importance of progesterone (P4) for maintenance of pregnancy, its role in cervical
ripening and uterine contractions is at least partly established and therefore, not surprisingly …

Objective Progestogen (vaginal progesterone or 17-alpha-hydroxyprogesterone caproate
[17OHP-C]) administration to patients at risk for preterm delivery is widely used for the …